Cancer Research Targets Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yuen, S. T.
Right arrow Articles by Leung, S. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yuen, S. T.
Right arrow Articles by Leung, S. Y.
[Cancer Research 62, 6451-6455, November 15, 2002]
© 2002 American Association for Cancer Research

Advances in Brief

Similarity of the Phenotypic Patterns Associated with BRAF and KRAS Mutations in Colorectal Neoplasia1

Siu T. Yuen, Helen Davies, Tsun L. Chan, Judy W. Ho, Graham R. Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Wendy W. Tsui, Annie S. Chan, P. Andrew Futreal, Michael R. Stratton2, Richard Wooster and Suet Y. Leung2

Departments of Pathology [S. T. Y., T. L. C., W. W. T., A. S. C., S. Y. L.], and Surgery [J. W. H.], University of Hong Kong, Queen Mary Hospital, Hong Kong, and Cancer Genome Project, The Wellcome Trust Sanger Institute, Hinxton, CB10 1SA, United Kingdom [H. D., G. R. B., C. C., P. S., S. E., P. A. F., M. R. S., R. W.]

Activation of the RAS/RAF/extracellular signal-regulated kinase-mitogen-activated protein kinase/extracellular signal-regulated kinase/mitogen-activated protein kinase pathway by RAS mutations is commonly found in human cancers. Recently, we reported that mutation of BRAF provides an alternative route for activation of this signaling pathway and can be found in melanomas, colorectal cancers, and ovarian tumors. Here we perform an extensive characterization of BRAF mutations in a large series of colorectal tumors in various stages of neoplastic transformation. BRAF mutations were found in 11 of 215 (5.1%) colorectal adenocarcinomas, 3 of 108 (2.8%) sporadic adenomas, 1 of 63 (1.6%) adenomas from familial adenomatous polyposis (FAP) patients, and 1 of 3 (33%) hyperplastic polyps. KRAS mutations were detected in 34% of carcinomas, 31% of sporadic adenomas, 9% of FAP adenomas, and no hyperplastic polyps. Eight of 16 BRAF mutations were V599E, the previously described hotspot, and none of these was associated with a KRAS mutation in the same lesion. The remaining eight mutations involve other conserved amino acids in the kinase domain, and 62.5% have a KRAS mutation in the same tumor. Our data suggest that BRAF mutations are, to some extent, biologically similar to RAS mutations in colorectal cancer because both occur at approximately the same stage of the adenoma-carcinoma sequence, both are associated with villous morphology, and both are less common in adenomas from FAP cases. By contrast, colorectal adenocarcinomas with BRAF mutations are associated with early Dukes’ tumor stages (P = 0.006) and no such relationship was observed for KRAS mutations. The presence in some colorectal neoplasms of mutations in both BRAF and KRAS suggests that modulation of the RAS-RAF-extracellular signal-regulated kinase-mitogen-activated protein kinase/extracellular signal-regulated kinase/mitogen-activated protein kinase signaling pathway may occur by mutation of multiple components.




This article has been cited by other articles:


Home page
 JCOHome page
F. Honecker, H. Wermann, F. Mayer, A. J.M. Gillis, H. Stoop, R. J.L.M. van Gurp, K. Oechsle, E. Steyerberg, J. Th. Hartmann, W. N.M. Dinjens, et al.
Microsatellite Instability, Mismatch Repair Deficiency, and BRAF Mutation in Treatment-Resistant Germ Cell Tumors
J. Clin. Oncol., May 1, 2009; 27(13): 2129 - 2136.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Wong, M. Belvin, S. Herter, K. P. Hoeflich, L. J. Murray, L. Wong, and E. F. Choo
Pharmacodynamics of 2-{4-[(1E)-1-(Hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl}ethan-1-ol (GDC-0879), a Potent and Selective B-Raf Kinase Inhibitor: Understanding Relationships between Systemic Concentrations, Phosphorylated Mitogen-Activated Protein Kinase Kinase 1 Inhibition, and Efficacy
J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 360 - 367.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. P. Hoeflich, S. Herter, J. Tien, L. Wong, L. Berry, J. Chan, C. O'Brien, Z. Modrusan, S. Seshagiri, M. Lackner, et al.
Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression
Cancer Res., April 1, 2009; 69(7): 3042 - 3051.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Zang, J. Gong, L. Luo, J. Zhou, X. Xiang, W. Huang, Q. Huang, X. Luo, M. Olbrot, Y. Peng, et al.
Characterization of Ser338 Phosphorylation for Raf-1 Activation
J. Biol. Chem., November 14, 2008; 283(46): 31429 - 31437.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. E. Schweppe, J. P. Klopper, C. Korch, U. Pugazhenthi, M. Benezra, J. A. Knauf, J. A. Fagin, L. A. Marlow, J. A. Copland, R. C. Smallridge, et al.
Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification
J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4331 - 4341.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
J J Y Sung, J Y W Lau, G P Young, Y Sano, H M Chiu, J S Byeon, K G Yeoh, K L Goh, J Sollano, R Rerknimitr, et al.
Asia Pacific consensus recommendations for colorectal cancer screening
Gut, August 1, 2008; 57(8): 1166 - 1176.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
D. R. English, J. P. Young, J. A. Simpson, M. A. Jenkins, M. C. Southey, M. D. Walsh, D. D. Buchanan, M. A. Barker, A. M. Haydon, S. G. Royce, et al.
Ethnicity and Risk for Colorectal Cancers Showing Somatic BRAF V600E Mutation or CpG Island Methylator Phenotype
Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1774 - 1780.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
O. N. Ikediobi, M. Reimers, S. Durinck, P. E. Blower, A. P. Futreal, M. R. Stratton, and J. N. Weinstein
In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation
Mol. Cancer Ther., June 1, 2008; 7(6): 1337 - 1346.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Suehiro, C. W. Wong, L. R. Chirieac, Y. Kondo, L. Shen, C. R. Webb, Y. W. Chan, A. S.Y. Chan, T. L. Chan, T.-T. Wu, et al.
Epigenetic-Genetic Interactions in the APC/WNT, RAS/RAF, and P53 Pathways in Colorectal Carcinoma
Clin. Cancer Res., May 1, 2008; 14(9): 2560 - 2569.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Sanchez-de-Abajo, M. de la Hoya, M. van Puijenbroek, A. Tosar, J.A. Lopez-Asenjo, E. Diaz-Rubio, H. Morreau, and T. Caldes
Molecular Analysis of Colorectal Cancer Tumors from Patients with Mismatch Repair Proficient Hereditary Nonpolyposis Colorectal Cancer Suggests Novel Carcinogenic Pathways
Clin. Cancer Res., October 1, 2007; 13(19): 5729 - 5735.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
C. Spittle, M. R. Ward, K. L. Nathanson, P. A. Gimotty, E. Rappaport, M. S. Brose, A. Medina, R. Letrero, M. Herlyn, and R. H. Edwards
Application of a BRAF Pyrosequencing Assay for Mutation Detection and Copy Number Analysis in Malignant Melanoma
J. Mol. Diagn., September 1, 2007; 9(4): 464 - 471.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
B. R. Davies, A. Logie, J. S. McKay, P. Martin, S. Steele, R. Jenkins, M. Cockerill, S. Cartlidge, and P. D. Smith
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models
Mol. Cancer Ther., August 1, 2007; 6(8): 2209 - 2219.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Hao, V. M. Muniz-Medina, H. Mehta, N. E. Thomas, V. Khazak, C. J. Der, and J. M. Shields
Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth
Mol. Cancer Ther., August 1, 2007; 6(8): 2220 - 2229.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. Vandrovcova, K. Lagerstedt-Robinsson, L. Pahlman, and A. Lindblom
Somatic BRAF-V600E Mutations in Familial Colorectal Cancer.
Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2270 - 2273.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
C. H.F. Chan, D. Cook, and C. P. Stanners
Increased colon tumor susceptibility in azoxymethane treated CEABAC transgenic mice
Carcinogenesis, September 1, 2006; 27(9): 1909 - 1916.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. R. James, T. Dumeni, M. S. Stark, D. L. Duffy, G. W. Montgomery, N. G. Martin, and N. K. Hayward
Rapid Screening of 4000 Individuals for Germ-line Variations in the BRAF Gene
Clin. Chem., September 1, 2006; 52(9): 1675 - 1678.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
I.-J. Kim, H. C. Kang, S.-G. Jang, K. Kim, S.-A Ahn, H.-J. Yoon, S. N. Yoon, and J.-G. Park
Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K-ras mutations
Carcinogenesis, March 1, 2006; 27(3): 392 - 404.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. J. Panka, W. Wang, M. B. Atkins, and J. W. Mier
The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells
Cancer Res., February 1, 2006; 66(3): 1611 - 1619.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Mercer, S. Giblett, S. Green, D. Lloyd, S. DaRocha Dias, M. Plumb, R. Marais, and C. Pritchard
Expression of Endogenous Oncogenic V600EB-raf Induces Proliferation and Developmental Defects in Mice and Transformation of Primary Fibroblasts
Cancer Res., December 15, 2005; 65(24): 11493 - 11500.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Beeram, A. Patnaik, and E. K. Rowinsky
Raf: A Strategic Target for Therapeutic Development Against Cancer
J. Clin. Oncol., September 20, 2005; 23(27): 6771 - 6790.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
W. L. Ince, A. M. Jubb, S. N. Holden, E. B. Holmgren, P. Tobin, M. Sridhar, H. I. Hurwitz, F. Kabbinavar, W. F. Novotny, K. J. Hillan, et al.
Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab
J Natl Cancer Inst, July 6, 2005; 97(13): 981 - 989.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
K. Krohn, D. Fuhrer, Y. Bayer, M. Eszlinger, V. Brauer, S. Neumann, and R. Paschke
Molecular Pathogenesis of Euthyroid and Toxic Multinodular Goiter
Endocr. Rev., June 1, 2005; 26(4): 504 - 524.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. C. Seales, G. A. Jurado, B. A. Brunson, J. K. Wakefield, A. R. Frost, and S. L. Bellis
Hypersialylation of {beta}1 Integrins, Observed in Colon Adenocarcinoma, May Contribute to Cancer Progression by Up-regulating Cell Motility
Cancer Res., June 1, 2005; 65(11): 4645 - 4652.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
C W Wong, Y S Fan, T L Chan, A S W Chan, L C Ho, T K F Ma, the Cancer Genome Project, S T Yuen, and S Y Leung
BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs
J. Clin. Pathol., June 1, 2005; 58(6): 640 - 644.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
K Busby and A Morris
Detection of BRAF mutations in colorectal tumours and peritoneal washings using a mismatch ligation assay
J. Clin. Pathol., April 1, 2005; 58(4): 372 - 375.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
R. Beach, A. O.-O. Chan, T.-T. Wu, J. A. White, J. S. Morris, S. Lunagomez, R. R. Broaddus, J.-P. J. Issa, S. R. Hamilton, and A. Rashid
BRAF Mutations in Aberrant Crypt Foci and Hyperplastic Polyposis
Am. J. Pathol., April 1, 2005; 166(4): 1069 - 1075.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Eszlinger, K. Krohn, K. Berger, J. Lauter, S. Kropf, M. Beck, D. Fuhrer, and R. Paschke
Gene Expression Analysis Reveals Evidence for Increased Expression of Cell Cycle-Associated Genes and Gq-Protein-Protein Kinase C Signaling in Cold Thyroid Nodules
J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1163 - 1170.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
P. Smyth, S. Finn, S. Cahill, E. O'Regan, R. Flavin, J. J. O'Leary, and O. Sheils
ret/PTC and BRAF Act as Distinct Molecular, Time-Dependant Triggers in a Sporadic Irish Cohort of Papillary Thyroid Carcinoma
International Journal of Surgical Pathology, January 1, 2005; 13(1): 1 - 8.
[Abstract] [PDF]

Home page
 JCOHome page
T. Nagasaka, H. Sasamoto, K. Notohara, H. M. Cullings, M. Takeda, K. Kimura, T. Kambara, D. G. MacPhee, J. Young, B. A. Leggett, et al.
Colorectal Cancer With Mutation in BRAF, KRAS, and Wild-Type With Respect to Both Oncogenes Showing Different Patterns of DNA Methylation
J. Clin. Oncol., November 15, 2004; 22(22): 4584 - 4594.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
C. Oliveira, J. L. Westra, D. Arango, M. Ollikainen, E. Domingo, A. Ferreira, S. Velho, R. Niessen, K. Lagerstedt, P. Alhopuro, et al.
Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status
Hum. Mol. Genet., October 1, 2004; 13(19): 2303 - 2311.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
T Kambara, L A Simms, V L J Whitehall, K J Spring, C V A Wynter, M D Walsh, M A Barker, S Arnold, A McGivern, N Matsubara, et al.
BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum
Gut, August 1, 2004; 53(8): 1137 - 1144.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Ikenoue, Y. Hikiba, F. Kanai, J. Aragaki, Y. Tanaka, J. Imamura, T. Imamura, M. Ohta, H. Ijichi, K. Tateishi, et al.
Different Effects of Point Mutations within the B-Raf Glycine-Rich Loop in Colorectal Tumors on Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase and Nuclear Factor {kappa}B Pathway and Cellular Transformation
Cancer Res., May 15, 2004; 64(10): 3428 - 3435.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Konishi, T. Yamochi, R. Makino, K. Kaneko, T. Yamamoto, H. Nozawa, A. Katagiri, H. Ito, K. Nakayama, H. Ota, et al.
Molecular Differences between Sporadic Serrated and Conventional Colorectal Adenomas
Clin. Cancer Res., May 1, 2004; 10(9): 3082 - 3090.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K. Fransen, M. Klintenas, A. Osterstrom, J. Dimberg, H.-J. Monstein, and P. Soderkvist
Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas
Carcinogenesis, April 1, 2004; 25(4): 527 - 533.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Shinozaki, A. Fujimoto, D. L. Morton, and D. S. B. Hoon
Incidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas
Clin. Cancer Res., March 1, 2004; 10(5): 1753 - 1757.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Casula, M. Colombino, M. P. Satta, A. Cossu, P. A. Ascierto, G. Bianchi-Scarra, D. Castiglia, M. Budroni, C. Rozzo, A. Manca, et al.
BRAF Gene Is Somatically Mutated but Does Not Make a Major Contribution to Malignant Melanoma Susceptibility: The Italian Melanoma Intergroup Study
J. Clin. Oncol., January 15, 2004; 22(2): 286 - 292.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Deng, I. Bell, S. Crawley, J. Gum, J. P. Terdiman, B. A. Allen, B. Truta, M. H. Sleisenger, and Y. S. Kim
BRAF Mutation Is Frequently Present in Sporadic Colorectal Cancer with Methylated hMLH1, But Not in Hereditary Nonpolyposis Colorectal Cancer
Clin. Cancer Res., January 1, 2004; 10(1): 191 - 195.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Ikenoue, Y. Hikiba, F. Kanai, Y. Tanaka, J. Imamura, T. Imamura, M. Ohta, H. Ijichi, K. Tateishi, T. Kawakami, et al.
Functional Analysis of Mutations within the Kinase Activation Segment of B-Raf in Human Colorectal Tumors
Cancer Res., December 1, 2003; 63(23): 8132 - 8137.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. Namba, M. Nakashima, T. Hayashi, N. Hayashida, S. Maeda, T. I. Rogounovitch, A. Ohtsuru, V. A. Saenko, T. Kanematsu, and S. Yamashita
Clinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers
J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4393 - 4397.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Wang, J. M. Cunningham, J. L. Winters, J. C. Guenther, A. J. French, L. A. Boardman, L. J. Burgart, S. K. McDonnell, D. J. Schaid, and S. N. Thibodeau
BRAF Mutations in Colon Cancer Are Not Likely Attributable to Defective DNA Mismatch Repair
Cancer Res., September 1, 2003; 63(17): 5209 - 5212.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. L. Chan, W. Zhao, Cancer Genome Project, S. Y. Leung, and S. T. Yuen
BRAF and KRAS Mutations in Colorectal Hyperplastic Polyps and Serrated Adenomas
Cancer Res., August 15, 2003; 63(16): 4878 - 4881.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Xu, R. M. Quiros, P. Gattuso, K. B. Ain, and R. A. Prinz
High Prevalence of BRAF Gene Mutation in Papillary Thyroid Carcinomas and Thyroid Tumor Cell Lines
Cancer Res., August 1, 2003; 63(15): 4561 - 4567.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Kumar, S. Angelini, K. Czene, I. Sauroja, M. Hahka-Kemppinen, S. Pyrhonen, and K. Hemminki
BRAF Mutations in Metastatic Melanoma: A Possible Association with Clinical Outcome
Clin. Cancer Res., August 1, 2003; 9(9): 3362 - 3368.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.